phentermine has been researched along with topiramate in 101 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.99) | 29.6817 |
| 2010's | 75 (74.26) | 24.3611 |
| 2020's | 25 (24.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W | 1 |
| Hay, M | 1 |
| Bays, H | 1 |
| Allison, DB; Day, WW; Gadde, KM; Peterson, CA; Ryan, DH; Schwiers, ML; Troupin, B | 1 |
| Shah, K; Villareal, DT | 1 |
| Malgarini, RB; Pimpinella, G | 1 |
| Cohen, PA | 1 |
| Allison, DB; Day, WW; Gadde, KM; Garvey, WT; Najarian, T; Peterson, CA; Schwiers, ML; Tam, PY; Troupin, B | 1 |
| Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M | 1 |
| Bays, HE; Gadde, KM | 1 |
| Goldfine, AB; Hiatt, WR; Thomas, A | 1 |
| Mullard, A | 1 |
| Akie, W | 1 |
| Mercer, SL | 1 |
| Bello, NT; Campbell, SC | 1 |
| Lauer, MS | 1 |
| Cameron, F; McKeage, K; Whiteside, G | 1 |
| Colman, E; Egan, A; Golden, J; Roberts, M; Rosebraugh, C; Weaver, J | 1 |
| Johnson, AM | 1 |
| Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J | 1 |
| Bowden, CH; DiDonato, KP; McCullough, PA; Winslow, DH | 1 |
| Bowden, CH; Davidson, MH; Day, WW; Oparil, S; Schwiers, M; Tonstad, S | 1 |
| Meyer, M; Smith, SM; Trinkley, KE | 1 |
| Hermayer, K; Holes-Lewis, KA; Malcolm, R; O'Neil, PM | 1 |
| Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P | 1 |
| Conrad, AO; Cosentino, G; Uwaifo, GI | 1 |
| Faria, AM; Halpern, A; Halpern, B | 1 |
| Garvey, WT | 1 |
| Padwal, RS; Rueda-Clausen, CF; Sharma, AM | 1 |
| Charakida, M; Finer, N; Tousoulis, D | 1 |
| Boulghassoul-Pietrzykowska, N; Franceschelli, J; Still, C | 1 |
| Kelly, EM; Tungol, AA; Wesolowicz, LA | 1 |
| Bohannon, NJ; Day, WW; Garvey, WT; Henry, R; Ryan, DH; Schwiers, M; Toplak, H; Troupin, B | 1 |
| Baretić, M | 1 |
| Aronne, LJ; Gadde, KM; Odeh, S; Peterson, C; Wadden, TA; Winslow, D | 1 |
| le Roux, CW; Miras, AD | 1 |
| Apovian, CM; Fujioka, K; Kushner, RF | 1 |
| Schwartz, LM; Woloshin, S | 1 |
| Astrup, A; Day, WW; Engeli, S; Finer, N; Jordan, J; Narkiewicz, K | 1 |
| Gadde, KM; Xiong, GL | 1 |
| Nakazato, M; Ueno, H | 1 |
| Ebbert, JO; Edakkanambeth Varayil, J; Hurt, RT | 1 |
| Aldhoon-Hainerová, I; Hainer, V | 1 |
| Hainer, V | 1 |
| Haywood, CJ; Houlihan, CA; Lee, FT; Neoh, SL; Proietto, J; Sumithran, P | 1 |
| Bray, GA | 1 |
| Ryan, DH | 1 |
| Cunningham, JW; Wiviott, SD | 1 |
| Bohannon, NJ; Dvorak, RV; Garvey, WT; Kushner, RF; Rueger, M; Ryan, DH; Troupin, B | 1 |
| Citrome, L | 1 |
| Rubio, MA | 1 |
| Acosta, A; Burton, D; Camilleri, M; Eckert, D; Iturrino, J; O'Neill, J; Shin, A; Vazquez-Roque, MI; Zinsmeister, AR | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Chen, H; Haseeb, S; He, X; Li, H; Li, W; Ni, Y; Xu, M; Zhou, Y | 1 |
| Aronne, LJ; Kumar, RB | 1 |
| Fujioka, K | 1 |
| Johnson, JL; Rolan, PE | 1 |
| Alfaris, N; Berkowitz, RI; Hopkins, CM; Minnick, AM; Wadden, TA | 1 |
| Bragg, R; Crannage, E | 1 |
| Crosby, RD; Gadde, KM; Kolotkin, RL; Peterson, CA | 1 |
| Chaudhry, UI; Durkin, N; Foreman, KS; Mikami, DJ; Needleman, BJ; Noria, SF; Schwartz, J; Suzo, A; Tychonievich, K; Wehr, AM | 1 |
| Megyeri, J; Nuffer, W; Trujillo, JM | 1 |
| Berghold, A; Horvath, K; Jeitler, K; Meschik, J; Posch, N; Semlitsch, T; Siebenhofer, A | 1 |
| Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z | 1 |
| Halpern, B; Mancini, MC | 1 |
| Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH | 1 |
| Gadde, KM; Pritham Raj, Y | 1 |
| Garvey, WT; Guo, F | 1 |
| Dixon, J; Lee, PC | 1 |
| Grabarczyk, TR | 1 |
| Andrews, EB; Anthony, MS; Cainzos-Achirica, M; Harding, A; Hunter, S; Kowey, PR; Nguyen, L; Peterson, C; Ritchey, ME; Rothman, KJ; Sager, PT; Thomas, S | 1 |
| Farhat, N; Gosselin, NH; Hsia, DS; Marier, JF; Peterson, C; Shih, W; Siegel, R; Williams, J | 1 |
| Adler, S; Bentley, JP; Dalai, SS; Najarian, T; Pajarito, S; Safer, DL; Toyama, H | 1 |
| Anderson, WA; Apovian, CM; Carmine, B; Hess, DT; Istfan, NW; Yu, L | 1 |
| Cohen, RV; Cummings, DE | 1 |
| Brown, SA; Izzy, M; Watt, KD | 1 |
| Alcorn, JL; Bolin, BL; Hays, LR; Lile, JA; Rayapati, AO; Reynolds, AR; Rush, CR; Stoops, WW | 1 |
| Lee, SY; Tak, YJ | 1 |
| Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S | 1 |
| Aronne, LJ; Redmond, IP; Shukla, AP | 1 |
| Lai, C; Lei, XG; Ruan, JQ; Sun, Z; Yang, X | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| Abu Dayyeh, BK; Abu Lebdeh, HS; Acosta, A; Calderon, G; Camilleri, M; Campos, A; Cifuentes, L; Clark, MM; Collazo-Clavell, ML; Garcia-Valencia, OA; Gonzalez-Izundegui, D; Grothe, K; Hurley, DL; Hurtado Andrade, MD; Mokadem, MA; Mundi, MS; Schmitz, K; Shah, M; Shan, KL; Sharma, M | 1 |
| DeConde, J; Grunvald, E | 1 |
| Kaur, N; Levin, A; Mainoo, NK; Perez, A | 1 |
| Morton, J; Tahrani, AA | 1 |
| Nolan, BJ; Proietto, J; Sumithran, P | 1 |
| Dhillon, S | 1 |
| Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG | 2 |
| Ard, JD; Beavers, DP; Edwards-Hampton, SA; Fernandez, A; Jayaprakash, MS; McNatt, S; Miller, GD | 1 |
| Hill, A; Levi, J; Venter, F; Wang, J | 1 |
| Jirapinyo, P; Thompson, CC | 1 |
| Di Leo, A; Giorgino, F; Iannone, A; Laviola, L; Natale, P; Nicolucci, A; Palmer, SC; Rendina, M; Strippoli, GFM | 1 |
| Aziz, Z; Bellows, BK; Hur, C; Kelly, AS; Lim, F; Tan, SX; Woo Baidal, JA | 1 |
| Mital, S; Nguyen, HV | 1 |
45 review(s) available for phentermine and topiramate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate | 2004 |
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Topics: Adipose Tissue; Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; Delayed-Action Preparations; Drug Approval; Drug Combinations; Drugs, Investigational; Fructose; Humans; Metabolic Diseases; Obesity; Phentermine; Practice Guidelines as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2010 |
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Topics: Animals; Anti-Obesity Agents; Appetite Depressants; Chemistry, Pharmaceutical; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Randomized Controlled Trials as Topic; Topiramate; United States; United States Food and Drug Administration | 2011 |
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss | 2012 |
Phentermine/topiramate for the treatment of obesity.
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Topiramate | 2013 |
Pharmacotherapy of obesity: clinical treatments and considerations.
Topics: Anti-Obesity Agents; Benzazepines; Drug Therapy, Combination; Fructose; Humans; Obesity; Phentermine; Topiramate | 2013 |
Phentermine and topiramate extended-release for the obesity: new kids on the block.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Obesity; Patents as Topic; Phentermine; Topiramate; Treatment Outcome; Weight Loss | 2013 |
Phentermine and topiramate for the management of obesity: a review.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fructose; Humans; Obesity; Phentermine; Topiramate | 2013 |
Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Dose-Response Relationship, Drug; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome | 2013 |
Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Fructose; Humans; Obesity; Overweight; Phentermine; Topiramate; Weight Loss | 2013 |
New pharmacological approaches for obesity management.
Topics: Appetite Depressants; Benzazepines; Drug Combinations; Fructose; Humans; Life Style; Obesity; Phentermine; Topiramate | 2013 |
Drug treatment of obesity in the cardiovascular patient.
Topics: Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Fructose; Humans; Lactones; Obesity; Orlistat; Phentermine; Topiramate | 2013 |
New medications for obesity management: changing the landscape of obesity treatment.
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Drugs, Investigational; Fructose; Humans; Lactones; Obesity; Orlistat; Phentermine; Topiramate; Weight Reduction Programs | 2013 |
Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Weight; Clinical Trials, Phase III as Topic; Female; Fructose; Humans; Male; Obesity; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss | 2013 |
Obesity drug therapy.
Topics: Anti-Obesity Agents; Appetite; Combined Modality Therapy; Comorbidity; Cost-Benefit Analysis; Cyclobutanes; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Combinations; Exercise Therapy; Fructose; Gastrointestinal Hormones; Humans; Incretins; Insulin; Insulin Secretion; Intestines; Lactones; Leptin; Life Style; Models, Biological; Neuropeptides; Obesity; Orlistat; Phentermine; Phytotherapy; Piperidines; Plant Preparations; Pyrazoles; Rimonabant; Topiramate | 2013 |
Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?
Topics: Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Feeding Behavior; Female; Fructose; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Homeostasis; Humans; Islet Amyloid Polypeptide; Lactones; Male; Minimally Invasive Surgical Procedures; Obesity, Morbid; Orlistat; Phentermine; Receptors, Glucagon; Topiramate; Treatment Outcome; Weight Loss | 2014 |
Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm.
Topics: Anti-Obesity Agents; Bariatric Surgery; Clinical Trials as Topic; Diet, Reducing; Drug Therapy, Combination; Evidence-Based Practice; Exercise; Female; Fructose; Humans; Male; Obesity; Phentermine; Topiramate; Weight Loss | 2013 |
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Topics: Aged; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Comorbidity; Drug Combinations; Female; Fructose; Humans; Male; Middle Aged; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Risk Factors; Topiramate; Treatment Outcome; Weight Loss | 2014 |
Combination phentermine/topiramate for obesity treatment in primary care: a review.
Topics: Anti-Obesity Agents; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Fructose; Humans; Obesity; Phentermine; Primary Health Care; Topiramate; Treatment Outcome; United States; Weight Loss | 2014 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
New pharmacological treatments for the management of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Topiramate; Treatment Outcome | 2014 |
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Medical treatment of obesity: the past, the present and the future.
Topics: Anti-Obesity Agents; Benzazepines; Drug Therapy, Combination; Fructose; Humans; Lactones; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss | 2014 |
The pharmacological and surgical management of adults with obesity.
Topics: Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Fructose; Humans; Lactones; Middle Aged; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Drug treatment of obesity: current status and future prospects.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2015 |
Efficacy comparison of medications approved for chronic weight management.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Benzazepines; Body Weight; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Female; Fructose; Humans; Obesity; Phentermine; Pilot Projects; Topiramate; Weight Loss | 2015 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2015 |
Combination phentermine and topiramate extended release in the management of obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Disease Management; Drug Combinations; Fructose; Humans; Life Style; Obesity; Phentermine; Randomized Controlled Trials as Topic; Risk Factors; Topiramate; Weight Loss | 2015 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2016 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Pressure; Cyclobutanes; Diet, Reducing; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Safety-Based Drug Withdrawals; Time; Topiramate; Weight Loss | 2016 |
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss | 2016 |
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate | 2017 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain | 2017 |
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Topics: Anti-Obesity Agents; Benzazepines; Clinical Trials as Topic; Fructose; Humans; Life Style; Liraglutide; Obesity; Phentermine; Topiramate; Weight Loss | 2017 |
Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.
Topics: Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Humans; Liraglutide; Liver Cirrhosis; Liver Transplantation; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Translational Science, Biomedical | 2021 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2021 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate | 2021 |
Use of Weight Loss Medications in Patients after Bariatric Surgery.
Topics: Anti-Obesity Agents; Bariatric Surgery; Humans; Liraglutide; Obesity; Phentermine; Postoperative Period; Topiramate; Weight Gain; Weight Loss | 2021 |
Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
Topics: Adult; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middle Aged; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome; Weight Loss | 2021 |
Benefits of weight loss of 10% or more in patients with overweight or obesity: A review.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Humans; Obesity; Overweight; Phentermine; Quality of Life; Topiramate; Weight Loss | 2022 |
Phentermine/Topiramate: Pediatric First Approval.
Topics: Adolescent; Adult; Anti-Obesity Agents; Child; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fructose; Humans; Non-alcoholic Fatty Liver Disease; Obesity; Phentermine; Sleep Apnea Syndromes; Sympathomimetics; Topiramate; Weight Loss | 2022 |
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Adult; Humans; Network Meta-Analysis; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Topiramate | 2023 |
12 trial(s) available for phentermine and topiramate
| Article | Year |
|---|---|
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Comorbidity; Double-Blind Method; Drug Combinations; Female; Fructose; Humans; Male; Middle Aged; Obesity; Overweight; Phentermine; Topiramate; Weight Loss; Young Adult | 2011 |
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Delayed-Action Preparations; Drug Combinations; Female; Fructose; Humans; Lipoproteins, LDL; Male; Middle Aged; Obesity, Morbid; Phentermine; Topiramate; Weight Loss; Young Adult | 2012 |
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; Fructose; Humans; Incidence; Intention to Treat Analysis; Least-Squares Analysis; Male; Metabolic Diseases; Middle Aged; Obesity; Overweight; Patient Dropouts; Phentermine; Time; Topiramate; Weight Loss | 2012 |
A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Topics: Administration, Oral; Adult; Aged; Anti-Obesity Agents; Appetite Depressants; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middle Aged; Obesity; Phentermine; Polysomnography; Prospective Studies; Sleep Apnea, Obstructive; Topiramate; Treatment Outcome | 2012 |
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Fructose; Humans; Life Style; Male; Metabolic Syndrome; Middle Aged; Phentermine; Placebos; Prediabetic State; Topiramate | 2014 |
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Topics: Adult; Anti-Obesity Agents; Delayed-Action Preparations; Drug Combinations; Female; Fructose; Humans; Male; Middle Aged; Obesity; Phentermine; Placebos; Topiramate; Treatment Outcome; Weight Loss | 2013 |
Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructose; Humans; Life Style; Male; Middle Aged; Obesity; Phentermine; Topiramate; Treatment Outcome; Weight Loss | 2014 |
Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.
Topics: Adult; Aged; Anti-Obesity Agents; Anxiety; Body Image; Body Mass Index; Cholecystokinin; Cohort Studies; Delayed-Action Preparations; Depression; Dipeptides; Drug Combinations; Fasting; Female; Fructose; Gastric Emptying; Ghrelin; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Obesity; Organ Size; Overweight; Peptide YY; Phentermine; Postprandial Period; Principal Component Analysis; Prospective Studies; Satiation; Self Efficacy; Stomach; Topiramate; Treatment Outcome | 2015 |
A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
Topics: Adolescent; Anti-Obesity Agents; Child; Double-Blind Method; Fructose; Humans; Obesity; Phentermine; Topiramate | 2020 |
A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.
Topics: Adolescent; Adult; Binge-Eating Disorder; Bulimia Nervosa; Cross-Over Studies; Drug Combinations; Female; Humans; Middle Aged; Phentermine; Topiramate; Young Adult | 2020 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Impact on Cardiovascular Health of Using Phentermine/Topiramate in Combination With Laparoscopic Sleeve Gastrectomy in Super Obesity.
Topics: Antihypertensive Agents; Gastrectomy; Humans; Laparoscopy; Obesity; Obesity, Morbid; Phentermine; Retrospective Studies; Topiramate; Treatment Outcome | 2023 |
44 other study(ies) available for phentermine and topiramate
| Article | Year |
|---|---|
Market watch: upcoming market catalysts in Q3 2010.
Topics: Anti-Obesity Agents; Benzazepines; Drug Approval; Drug Combinations; Drug Evaluation, Preclinical; Fructose; Humans; Phentermine; Topiramate; United States; United States Food and Drug Administration | 2010 |
Combination treatment to CONQUER obesity?
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Fructose; Humans; Life Style; Obesity; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome; Weight Loss | 2011 |
Phentermine plus topiramate in the treatment of obesity.
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Heart Valve Diseases; Humans; Obesity; Phentermine; Topiramate; Weight Loss | 2011 |
Phentermine plus topiramate in the treatment of obesity.
Topics: Anti-Obesity Agents; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2011 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss | 2012 |
Panel meeting prompts excitement for antiobesity drug.
Topics: Anti-Obesity Agents; Drug Approval; Drug Combinations; Fructose; Humans; Phentermine; Topiramate; United States | 2012 |
Market watch: Upcoming market catalysts in Q2 2012.
Topics: Drug Approval; Drug Therapy, Combination; Fructose; Humans; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration | 2012 |
ACS chemical neuroscience molecule spotlight on Qnexa.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials, Phase III as Topic; Comorbidity; Double-Blind Method; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Overweight; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Treatment Outcome; United States; United States Food and Drug Administration; Weight Loss | 2011 |
Two anti-obesity hopefuls and their safety.
Topics: Adult; Anti-Obesity Agents; Benzazepines; Dose-Response Relationship, Drug; Drug Combinations; Drugs, Investigational; Female; Fructose; Heart Valve Diseases; Humans; Male; Obesity; Phentermine; Pregnancy; Tachycardia; Teratogens; Topiramate; Weight Loss | 2012 |
Lemons for obesity.
Topics: Appetite Depressants; Data Interpretation, Statistical; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Risk Assessment; Topiramate; United States; United States Food and Drug Administration | 2012 |
Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
Topics: Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; Drug and Narcotic Control; Drug Combinations; Evidence-Based Medicine; France; Fructose; Humans; Narcotics; Obesity; Phentermine; Topiramate; Treatment Outcome; Weight Loss | 2012 |
Phentermine and topiramate extended release (Qsymia™): first global approval.
Topics: Anti-Obesity Agents; Appetite Depressants; Clinical Trials as Topic; Delayed-Action Preparations; Fructose; Humans; Obesity; Phentermine; Randomized Controlled Trials as Topic; Topiramate | 2012 |
The FDA's assessment of two drugs for chronic weight management.
Topics: Abnormalities, Drug-Induced; Anti-Obesity Agents; Benzazepines; Delayed-Action Preparations; Drug Approval; Drug Combinations; Female; Fructose; Humans; Obesity; Phentermine; Pregnancy; Serotonin Receptor Agonists; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2012 |
Two new drugs approved for obesity.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Drug Approval; Drug Combinations; Fructose; Humans; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration | 2012 |
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
Topics: Anti-Obesity Agents; Biomarkers; Body Mass Index; Cardiovascular Diseases; Comorbidity; Delayed-Action Preparations; Female; Fructose; Humans; Male; Middle Aged; Obesity; Phentermine; Risk; Topiramate | 2013 |
Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Topics: Anti-Obesity Agents; Appetite Depressants; Drug Approval; Drug Combinations; European Union; Female; Fructose; Humans; Obesity; Overweight; Phentermine; Pregnancy; Topiramate; United States | 2013 |
Topiramate and phentermine: a long story....
Topics: Anti-Obesity Agents; Appetite Depressants; Fructose; Humans; Obesity; Phentermine; Substance-Related Disorders; Topiramate | 2013 |
High demand likely for prescription weight-control drugs.
Topics: Appetite Depressants; Benzazepines; Drug Utilization; Fructose; Humans; Obesity; Phentermine; Prescription Drugs; Topiramate; United States; Weight Loss | 2012 |
The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Topics: Anti-Obesity Agents; Benzazepines; Female; Fructose; Humans; Male; Obesity; Phentermine; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2014 |
Combination phentermine and topiramate for weight maintenance: the first Australian experience.
Topics: Anti-Obesity Agents; Australia; Body Mass Index; Drug Therapy, Combination; Follow-Up Studies; Fructose; Humans; Medical Audit; Obesity; Phentermine; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Topiramate; Treatment Failure; Treatment Outcome; Weight Loss | 2014 |
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration | 2014 |
Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study.
Topics: Chromatography, Liquid; Fructose; Humans; Ions; Phentermine; Pioglitazone; Plasma; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Thiazolidinediones; Topiramate | 2015 |
Paradoxical topiramate-induced hyperphagia successfully treated with phentermine in a woman with migraine.
Topics: Appetite Depressants; Drug Therapy, Combination; Female; Fructose; Humans; Hyperphagia; Male; Middle Aged; Migraine Disorders; Neuroprotective Agents; Phentermine; Topiramate; Weight Gain | 2015 |
Review of pharmacotherapy options for the management of obesity.
Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States | 2016 |
Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
Topics: Adult; Body Mass Index; Body Weight; Depression; Female; Fructose; Health Status; Humans; Male; Middle Aged; Obesity; Outcome Assessment, Health Care; Phentermine; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Topiramate; Weight Loss | 2016 |
Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review.
Topics: Adult; Anti-Obesity Agents; Bariatric Surgery; Diet, Reducing; Exercise Therapy; Female; Fructose; Humans; Laparoscopy; Male; Middle Aged; Obesity; Phentermine; Retrospective Studies; Topiramate; Weight Loss | 2016 |
Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructose; Humans; Life Style; Male; Middle Aged; Obesity; Phentermine; Topiramate; Waist Circumference; Weight Loss | 2017 |
Pharmacotherapy for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Body Mass Index; Drug Therapy; Drug Therapy, Combination; Fructose; Humans; Incretins; Lactones; Liraglutide; Obesity; Orlistat; Phentermine; Topiramate | 2017 |
Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
Topics: Adult; Aged; Anti-Obesity Agents; Benzazepines; Body Weight; Cohort Studies; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Obesity; Orlistat; Phentermine; Retrospective Studies; Topiramate; United States; United States Department of Veterans Affairs; Weight Loss | 2018 |
Cardiovascular Safety During and After Use of Phentermine and Topiramate.
Topics: Adolescent; Adult; Anti-Obesity Agents; Drug Combinations; Female; Heart Rate; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Obesity; Phentermine; Retrospective Studies; Stroke; Topiramate; Weight Loss; Young Adult | 2019 |
The Mitigating Effect of Phentermine and Topiramate on Weight Regain After Roux-en-Y Gastric Bypass Surgery.
Topics: Adult; Anti-Obesity Agents; Female; Gastric Bypass; Humans; Male; Middle Aged; Phentermine; Postoperative Period; Retrospective Studies; Topiramate; Weight Gain | 2020 |
Weight Regain After Bariatric/Metabolic Surgery: A Wake-Up Call.
Topics: Bariatric Surgery; Gastric Bypass; Humans; Obesity, Morbid; Phentermine; Topiramate; Weight Gain | 2020 |
Topiramate-phentermine combinations reduce cocaine self-administration in humans.
Topics: Adult; Cocaine; Cocaine-Related Disorders; Drug Combinations; Female; Fructose; Humans; Male; Middle Aged; Phentermine; Self Administration; Topiramate; Young Adult | 2021 |
Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.
Topics: Adult; Anti-Obesity Agents; Female; Humans; Male; Middle Aged; Obesity; Phentermine; Topiramate; Weight Loss | 2022 |
Phentermine-topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report.
Topics: Adult; Anti-Obesity Agents; Feeding and Eating Disorders; Fructose; Humans; Male; Obesity; Phentermine; Quality of Life; Sleep; Topiramate | 2022 |
Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Nutrition Surveys; Obesity; Orlistat; Phentermine; Prevalence; Topiramate; United States; Weight Loss | 2022 |
Intensive management of obesity in people with Prader-Willi syndrome.
Topics: Child; Humans; Liraglutide; Obesity; Phentermine; Prader-Willi Syndrome; Retrospective Studies; Topiramate; Weight Loss | 2022 |
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male; Metformin; Obesity; Phentermine; Pregnancy; Topiramate | 2022 |
Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment.
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Health Care Costs; Health Services Accessibility; Liraglutide; Naltrexone; Orlistat; Phentermine; Topiramate | 2023 |
Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
Topics: Anti-Obesity Agents; Contraceptive Agents; Female; Fructose; Humans; Obesity; Phentermine; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; Risk Evaluation and Mitigation; Topiramate; Weight Loss | 2023 |
Combining transoral outlet reduction with pharmacotherapy yields similar 1-year efficacy with improved safety compared with surgical revision for weight regain after Roux-en-Y gastric bypass (with videos).
Topics: Gastric Bypass; Humans; Phentermine; Reoperation; Retrospective Studies; Topiramate; Weight Gain; Weight Loss | 2023 |
Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.
Topics: Adolescent; Cost-Benefit Analysis; Female; Humans; Liraglutide; Male; Pediatric Obesity; Phentermine; Topiramate; United States | 2023 |
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
Topics: Adolescent; Anti-Obesity Agents; Child; Cost-Benefit Analysis; Female; Humans; Liraglutide; Male; Obesity; Obesity, Morbid; Orlistat; Phentermine; Topiramate | 2023 |